Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 7, 2011 - Issue
Submit an article Journal homepage
75
Views
8
CrossRef citations to date
0
Altmetric
Review

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

Bruno Gori1 Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy
,
Serena Ricciardi1 Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy
,
Alberto Fulvi1 Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy
,
Salvatore Intagliata2 Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
,
Ester Del Signore1 Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy
&
Filippo de Marinis1 Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, ItalyCorrespondence[email protected]
Pages 429-440 | Published online: 17 Nov 2011

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Martin Reck. (2015) Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. Expert Review of Anticancer Therapy 15:5, pages 579-594.
Read now
Hannah V Woodcock, Philip L Molyneaux & Toby M Maher. (2013) Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Design, Development and Therapy 7, pages 503-510.
Read now

Articles from other publishers (6)

Claudia Dallinger, Dirk Trommeshauser, Kristell Marzin, Andre Liesener, Rolf Kaiser & Peter Stopfer. (2016) Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer. The Journal of Clinical Pharmacology 56:11, pages 1387-1394.
Crossref
Sohita Dhillon. (2015) Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology. Targeted Oncology 10:2, pages 303-310.
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs 391 491 .
Jean-Pierre Droz, Jaques Medioni, Christine Chevreau, Helene De Mont-Serrat, Michael Merger, Peter Stopfer, Rolf Kaiser & Stephane Oudard. (2014) Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. Anti-Cancer Drugs 25:9, pages 1081-1088.
Crossref
Gonzalo Fernandez-Fuente, Pilar Mollinedo, Lara Grande, Alfonso Vazquez-Barquero & Jose L. Fernandez-Luna. (2014) Culture Dimensionality Influences the Resistance of Glioblastoma Stem-like Cells to Multikinase Inhibitors. Molecular Cancer Therapeutics 13:6, pages 1664-1672.
Crossref
Xue-Yuan Wu, Wei Ma, Kiran Gurung & Chi-Hua Guo. (2013) Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy. Journal of the Formosan Medical Association 112:3, pages 115-124.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.